9月30日，翰森制药盘中上涨3.16%，报34.58港元，成交额1.24亿港元。
消息面上，摩根大通9月28日发布研报指出，默沙东与第一三共自愿撤回其B7-H3 ADC药物ifinatamab deruxtecan用于经治广泛期小细胞肺癌的美国生物制品许可申请，从竞争时序角度看，对翰森制药/GSK的Ris-Rez属增量正面。小摩维持翰森制药"增持"评级，目标价50港元。此外，翰森制药核心ADC产品HS-20093的小细胞肺癌及骨肉瘤两项适应症上市申请均已获NMPA受理并纳入优先审评。今日制药板块整体走强，石药集团涨6.39%、恒瑞医药涨6.01%、中国生物制药涨3.96%，板块共振亦对股价形成提振。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.